Tasly’s Modernized TCMs To Be Included In South African Medical Insurance
This article was originally published in PharmAsia News
Executive Summary
Tianjin Tasly Group's seven modernized traditional Chinese medicines including Cardiotonic Pill have been confirmed as procurement products by the South African government for its medical insurance catalog. The China firm, in pursuing a globalization strategy, set up its South African branch in 2002 and has since seen its sales in the continent soar from $100,000 to an impressive $80 million in 2007. Cardiotonic Pill, Tasly's key product, has completed trademark registration in 34 countries and regions. The medicine is currently undergoing FDA and EMEA Phase ? and ? clinical trials. Tasly is using this opportunity to promote TCM, especially modernized traditional medicines, and gain entry into the mainstream market of developed countries. (Click here for more - Chinese language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.